2013


To access this material please log in or register

Register Authorize
2013/№6

Beta-blockers: Time of trials or burden of trials? An endurance test

Ageev F. T.
Federal State Budgetary Institution, “Russian Cardiology Research and Production Complex” of the RF Ministry of Health Care, 3rd Cherepkovskaya 15a, Moscow 121552

Keywords: beta-adrenergic blocker agents, treatment, cardiovascular diseases

DOI: 10.18087/rhj.2013.6.1897

This review evalutes the publications, describing different aspects of the of the beta-blockers usage at cardio-vascular diseases.
  1. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366 (9496):1545–1553.
  2. Elliott WJ, Childers WK. Should β-blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities? Curr Cardiol Rep. 2011;13 (6):507–516.
  3. Bangalore S, Steg G, Deedwania P et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308 (13):1340–1349.
  4. Bouri S, Shun-Shin MJ, Cole GD et al. Meta-analisis of secure randomized controlled trials of β-Blockade to prevent perio­perative death in non-cardiac surgery. Heart. 2013 Jul 31. doi: 10.1136 / heartjnl-2013–304262. [Epub ahead of print].
  5. Rienstra M, Damman K, Mulder BA, et al. Beta-blockers and outcome in heart failure and atrial fibrillation. A meta-analysis. JACC: Heart Fail. 2013;1 (1):21–28.
  6. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372 (9641):807–816.
  7. Swedberg K, Komajda M, Bohm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376 (9744):875–885.
  8. Гиляревский С. Р., Орлов В. А., Кузьмина И. М. и др. Изменение представлений о роли β-блокаторов в лечении сердечно-сосудистых заболеваний. Русский медицинский журнал. Кардиология. 2013;4:231–237.
  9. Лопатин Ю. М. От результатов исследования BEAUTIFUL к результатам исследования SHIFT: «прекрасная» возможность внести «изменение» в современные рекомендации. Кардиология. 2011;51 (5):85–90.
  10. Согласованное мнение экспертов Общества специалистов по сердечной недостаточности. Результаты исследования SHIFT и рекомендации по включению Кораксана в схему лечения пациентов с ХСН и синусовым ритмом. Журнал Сердечная Недостаточность. 2011;12 (2):117–118.
  11. Stiles S. Friend or Foe? Digoxin for Systolic HF Ups Mortality in Cohort Study. Available at: http://www.medscape.com / viewarticle / 811298.
  12. The clinical management of primary hypertension in adults. Available at: http://www.nice.org.uk / nicemedia / live / 13561 / 56008 / 56008.pdf.
  13. Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004‑BHS IV. J Hum Hypertens. 2004;18 (3):139–185.
  14. Schmidt AC, Graf C, Brixius K, Scholze J. Blood pressure-lowe­ring effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig. 2007;27 (12):841–849.
  15. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs. 2007;67 (8):1097–1107.
  16. Dhakam Z, Yasmin, McEniery CM et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008;26 (2):351–356.
  17. Cockcroft JR, Pedersen ME. β-blockade: benefits beyond blood pressure reduction? J Clin Hypertens (Greenwich). 2012;14 (2):112–120.
  18. Глезер М. Г., Бойко Н. В., Абильдинова А. Ж. и др. Сравнительная эффективность лечения небивололом и бисопрололом больных артериальной гипетензией. Кардиоваск. тер. проф. 2004;3 (5):43–50.
  19. Жубрина Е. С., Овчинников А. Г., Середенина Е. М. и др. Эффективность амбулаторного перевода больных с ХСН с «нереко­мендованных» при этом заболевании β-адрено­блока­торов на небиволол или бисопролол. Журнал Сердечная недостаточность. 2009;10 (3):132–136.
  20. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH / ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34 (28):2159–2219.
  21. Wood S. Right Drugs, Inadequate Dose: Do AMI Performance Measures Need Dosing Data? Available at: http://www.medscape.com / viewarticle / 809807.
  22. Kumbhani DJ, Steg PG, Cannon CP et al. Adherence to secon­dary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med. 2013;126 (8):693–700.
  23. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34 (38):2949–3003.
  24. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная недостаточность. 2013;14 (7): 379–472.
  25. Barron AJ, Zaman N, Cole GD et al. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: Recommendations for patient information. Int J Cardiol. 2013;168 (4):3572–3579.
  26. Beta-blockers in HF Get Bum Rap for Most «Side Effects,» Says Study. Available at: http://www.medscape.com / viewarticle / 807788? t=1&topol=1
  27. Агеев Ф. Т. Письмо редактору. Журнал Сердечная недостаточность. 2011;12 (5):312–316.
  28. Агеев Ф. Т. Исследование SHIFT: сдвиг в правильном направлении? Кардиология. 2012;52 (1):83–85.
  29. Heart failure: ivabradine is no better than optimised beta-blocker therapy. Prescrire Int. 2011;20 (118):189–190.
  30. Massé JF. Stable angina: role of ivabradine unchanged between 2006 and 2010. Prescrire Int. 2010;19 (110):264; author reply 264–265.
  31. Sarraf M, Francis GS. It is all about heart rate. Or is it? J Am Coll Cardiol. 2012;59 (22):1946–1947.
  32. Ivabradine: new drug. Best avoided in stable angina. Prescrire Int. 2007;16 (88):53–56.
  33. McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150 (11):784–794.
  34. Flather M, Shibata M, Coats A et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26 (3):215–225.
  35. Dobre D, van Veldhuisen DJ, Mordenti G et al. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure. Data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with heart failure (SENIORS) Trial. Am Heart J. 2007;154 (1):109–115.
  36. MERIT-HF Study Group. Effect of metoprolol CR / XL in chro­nic heart failure: metoprolol CR / XL Randomized intervention trial in congestive heart failure (MERIT HF) Lancet. 1999;353 (9169):2001–2007.
  37. Fiuzat M, Wojdyla D, Kitzman D et al. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. J Am Coll Cardiol. 2012;60 (3):208–215.
  38. Гиляревский С. Р., Кузьмина И. М., Голшмид М. В. Достижение целевых доз лекарственных препаратов или целевых показателей: что должно считаться главным условием оптимального снижения риска развития осложнений сердечно-сосудистого заболевания? Артериальная гипертензия.2013;19 (3):204–211.
  39. Swedberg K, Komajda M, Böhm M et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59 (22):1938–1945.
  40. Krum H. Controversal issues in heart failure. High heart rate: maximise beta-blockers rather than add ivabradine. Oral presentation on ESC Congress, 2011, Paris.
  41. Mitchell LB. The impotance of beta-blockers in patients with heart failure: Resynchronization-defibrillation for ambulatory heart failure trial analysis (RAFT). Oral presentation on ESC Congress, 2013, Amsterdam.
  42. Poldermans D, Bax JJ, Boersma E et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and European Society of Anaesthesiology (ESA). Eur Heart J. 2009;30 (22):2769–2812.
  43. Прогнозирование и профилактика кардиальных осложнений внесердечных хирургических вмешательств. Национальные рекомендации. Приложение 3 к журналу Кардиоваскулярная терапия и профилактика 2011;10 (6):3–28.
  44. O'Riordan M. Perioperative beta-blocker controversy begins again with new meta-analysis. Available at: http://www.medscape.com / viewarticle / 808775
  45. Sipahi I, Debanne SM, Rowland DY et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11 (7):627–636.
  46. Wang KL, Liu CJ, Chao TF et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol. 2012;60 (14):1231–1238.
  47. van Vark LC, Bertrand M, Akkerhuis KM et al. Angotensin-converting enzymes reduce mortality in hypertension: a meta-ana­lysis of randomized clinical trials of rennin-angiotensin-aldosterone system inhibitors involving 158998 patients. Eur Heart J. 2012;33 (16):2088–2097.
  48. Петрухина А. А. Прогноз и лечение хронической сердечной недостаточности (данные 30‑летнего наблюдения). Автореф. дис…. канд. мед. наук. – М., 2008.
  49. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33 (14):1787–1847.
Ageev F. T. Beta-blockers: Time of trials or burden of trials? An endurance test. Russian Heart Journal. 2013;12(6):345-354

To access this material please log in or register

Register Authorize
Ru En